Dementia, Plus APOE Panel
Use
This test is indicated for individuals with features suggestive of dementia, especially those with early-onset symptoms before age 65, or who have a family history of Alzheimer disease or frontotemporal dementia. It aims to provide diagnoses that can inform clinical management and family planning. The test analyzes 19 genes related to dementia, offering insights into genetic predispositions.
Special Instructions
STAT testing is available, with a surcharge that applies if delivered after 16 days and a blood sample has been submitted. Testing options include Exome or Genome platforms. Ordering must be completed using an online order or a paper test requisition form accompanied by a labeled specimen.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. Results should be interpreted by a qualified healthcare provider, taking into account clinical features and family history to ensure accurate diagnosis and appropriate clinical management.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided